Literature DB >> 6377882

The pharmacokinetics of antibiotics used to treat peritoneal dialysis-associated peritonitis.

C A Johnson, S W Zimmerman, M Rogge.   

Abstract

Antibiotics continue to be used frequently to treat CAPD-associated peritonitis. Selection of appropriate antibiotic doses and routes of administration has been based largely upon clinical experience. Early pharmacokinetic studies utilized patients being treated with IPD. The relevance of these studies to CAPD remains unknown. Little information exists on the effects of peritonitis on peritoneal drug transport. Until the effects of peritonitis during CAPD are better understood, pharmacokinetic data will be of limited value in designing specific treatment recommendations for this common complication of peritoneal dialysis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6377882     DOI: 10.1016/s0272-6386(84)80020-7

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  4 in total

1.  Pharmacokinetics of cefepime in patients undergoing continuous ambulatory peritoneal dialysis.

Authors:  R H Barbhaiya; C A Knupp; M Pfeffer; D Zaccardelli; G M Dukes; W Mattern; K A Pittman; L J Hak
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

2.  Pharmacokinetics and pharmacodynamics of cefoperazone-sulbactam in patients on continuous ambulatory peritoneal dialysis.

Authors:  C A Johnson; S W Zimmerman; D P Reitberg; T J Whall; J E Leggett; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

Review 3.  Clinical pharmacokinetics during continuous ambulatory peritoneal dialysis.

Authors:  C A Taylor; E Abdel-Rahman; S W Zimmerman; C A Johnson
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

4.  In vitro bactericidal activities of gentamicin, cefazolin, and imipenem in peritoneal dialysis fluids.

Authors:  D C Halstead; J Guzzo; J A Giardina; A E Geshan
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.